UTHR

$524.28-2.72 (-0.52%)

Market ClosedAs of Mar 20, 8:00 PM UTC

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$524.28
Potential Upside
14.3%
Whystock Fair Value$599.23
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally....

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.81
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
17.50%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.28

Recent News

Investor's Business Daily
Mar 20, 2026

Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 19, 2026

2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 18, 2026

1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 18, 2026

CPRX vs. UTHR: Which Stock Is the Better Value Option?

CPRX vs. UTHR: Which Stock Is the Better Value Option?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 16, 2026

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

BEARISH
Negative press. News cycle fixated on risk factors or misses.